Pacira BioSciences, Inc.

Rank #95Hypergrowth

PCRX · Nasdaq · Healthcare

Pacira BioSciences, Inc. (PCRX) — Rank #95 by gross profitability (GP/assets 0.46) · ROE 1.0% · Piotroski F-Score N/A.

As-of 2026-09-15 · CIK 0001396814 · all metrics point-in-time as of the filing date.

About

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc.

was incorporated in 2006 and is headquartered in Brisbane, California.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
State: DE
Filer Category: Large accelerated filer
Fiscal Year End: December 31
Website: pacira.com

Price History

PCRX-55.5% · -14.9% CAGRSPY+80.5% · +12.5% CAGR

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

$933.73M

P/E (annual)

148.3

P/S (annual)

1.3

P/B

1.4

P/OCF (annual)

6.1

Shareholder Yield

-3.1%

Employees

825

Industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

Signal Flags

2 green2 yellow1 red

Revenue growth acceleratingGrowth rate increasing year over year

Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 2-quarter streak

Dilution above 2%Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation

Disclosure regressionA previously-disclosed line item is no longer reported — worth checking the filing for why

Operating margin decliningOperating margin lower than prior year

Quality Profile

Profitability

1/1 pass

GP / assets

0.46

Return on equity

1.0%

Gross margin trend

PASS

Safety

1/1 pass

Balance-sheet safety

PASS

Debt / equity

0.85

Current ratio

5.04×

Net cash

-$112.09M

Cash Flow

3/3 pass

Positive FCF

PASS

Cash-backed earnings

PASS

Accruals healthy

PASS

SBC / revenue

7.9%

Growth

1/2 pass

Revenue growth

69.1%

Piotroski F-Score

N/A

Share dilution

3.1%

Terry Smith quality gate

Passes 2/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

-5.4%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Dilution drag: 3.1% — per-share value needs a total required return of -2.3% once share-count change is priced in.

vs. own 6-year median revenue growth: 14.3%

within its own history

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

-8.9%

r = 10% (base)

-5.4%

r = 12%

-2.3%

Net debt / market cap: 10.5%

Base FCF: $136.7M3Y mean FCF: $59.8M

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

72.5xFair

21.8xmed 72.5x1431.5x

P / S

Price / revenue per share

5.6xFair

4.3xmed 7.0x30.3x

P / B

Price / book value per share

4.2xCheap

4.2xmed 7.0x62.9x

P / GP

Price / gross profit per share

7.6xFair

6.3xmed 10.6x114.0x

P / FCF

Price / free cash flow per share

38.1xCheap

33.3xmed 64.9x1135.0x

Disclosure regression check

A previously-disclosed line item is no longer reported. Worth checking the filing for why.

Interest expenseCost structure

last seen FY2022

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Gross profitability (GP / assets)

0.46

Primary signal (Novy-Marx).

4th of 9 SIC 2834 peers

Return on equity

1.0%

Gross margin

79.4%

4th of 9 SIC 2834 peers

Revenue growth (YoY)

69.1%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

	2018	2019	2020	2021
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

Earnings CAGR (3Y)

-23.8%

FCF CAGR (3Y)

—

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.85

5th of 9 SIC 2834 peers (best = lowest)

Current ratio

5.04×

2nd of 9 SIC 2834 peers

Quick ratio

3.14×

Net cash

-$112.09M

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$136.66M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

18.43

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

7.9%

Stock-based comp intensity.

Piotroski F-Score

F-Score

N/A

Only 8/9 components determinable.

Lifecycle Phase History

2016-2018

2019

2020

2021

20162021

Startup

Hypergrowth

Value

View full financial statements →